CONFERENCE UPDATE: ACC 2023

Incorporation of sotatercept into the background PAH therapy proven to be beneficial: The STELLAR phase 3 trial

CARDIOLOGY
29 Apr 2023

Get access to our exclusive articles.
Related Articles

Recalibrating pulmonary vascular resistance to predict heart failure

In patients with pulmonary hypertension, an elevated pulmonary vascular resistance (PVR) of 3.0 Wood units (WU) or more has been known to be associated with poor clinical prognosis.1 In a recent study published in The Lancet

CARDIOLOGY
29 Oct 2020